Bilateral Buzz on IPRs’


A fortnight of hectic parlays on trade negotiations where key accords where signed and strategic understandings arrived at . Swiss Fondue and fine Basmati do not a meal together make’, but yes, the Indian bilateral menu has been served with a generous serving of Swiss and Pakistani fare comprising of key IPR issues. India and Switzerland on Tuesday signed a memorandum of understanding (MoU) on safeguarding intellectual property rights (IPRs). The agreement envisages setting up of a joint committee to…


Read More »

SPICYIP TIDBITS


1. Asia Pacific Countries wish to copy Section 3(d) The ET reports: “More than 10 countries in the Asia-Pacific region are planning to adopt the much-debated provision which makes it difficult for drug makers to get patent protection for anything less than breakthroughs in pharmaceutical research. The provision describes what sort of pharmaceutical substance is worthy of a patent. The idea is to prevent companies from blocking the entry of cheaper rival products by passing off old medicines in new…


Read More »
Uncategorized

Genetic Patent – Law & Strategy by Dr. Kalyan


Biotechnology is one areas of technology that has influenced patent law like no other. It poses several challenging questions for patent jurisprudence: What ought to be the optimal patentability requirements for micro-organisms and genetic inventions? Do such inventions satisfy the requirements of novelty, non obviousness and utility? More importantly do they pose ethical and moral issues? Dr. Kalyan, in his book titled Genetic Patent – Law & Strategy, endeavours to address the aforesaid issues in a comprehensive manner, with particular…


Read More »

SPICY TIDBITS


Starting today, we’re beginning a new section titled “Spicy Tidbits” that will bring you short announcements of leading news in the world of IP and innovation law/policy, in so far as they have some relevance for India. 1. The US moves ahead with its WTO complaint against China, asking for the establishment of a panel. The International Herald Tribune reports: “The Bush administration has asked the World Trade Organization to rule in a complaint against China over the piracy of…


Read More »
Competition Law

THE RESURGENCE OF PRICE CONTROLS IN INDIA


In an earlier blog posting, I’d noted: “…pharmaceutical patents are not “bad” per se, as some of the statements in the press would have us believe—rather, as with most other things in life, they are susceptible to “abuse”. In this regard, it is important to strike a distinction between the grant of a patent and the regulation of its “use”. Our fears of a prospective abuse of a patent and excessively high prices should not cause us to deny patent…


Read More »
Patent

THE NOVARTIS PATENT DISPUTE: OF "SPINS" AND EMPTY RHETORIC


A couple of days back, in a legal dispute involving the patentability of Novartis’s famed anticancer drug, Gleevec, the Madras High Court ruled that section 3(d) of the Indian Patents Act was constitutional. It also held that it lacked jurisdiction to rule on whether or not section 3(d) contravened TRIPS–and that the appropriate forum to adjudicate this issue was the WTO. I’d hinted at the excessive spin on this judgment by interested stakeholders in an earlier blog posting. Let me…


Read More »

NOVARTIS CASE AT IPAB STAYED….


In a rather sensible move, the Chennai High Court has temporarily stayed the IPAB proceeding, pursuant to a complaint by Novartis that Chandrasekharan may be a biased party and ought not to sit in judgment over the appeal. SPICYIP has been reiterating time and again that Chandrasekharan ought to be replaced–else an otherwise strong case for the government could get dragged on owing to this infirmity. The ET Reports: “Hearings in Novartis’ appeal against the rejection of patent for its…


Read More »
Drug Regulation Patent

"Suicide" Inducing Drug in India: Need For More Stringent Drug Regulation


Bloomberg reports on a very troubling case of a “suicide inducing” diet control drug, that though not likely to be approved in the US, has been approved in India. It notes, in pertinent part: ” Sanofi-Aventis SA’s Acomplia weight- loss pill, linked to suicide, is becoming popular in generic form in India. That may end the product’s chances of ever reaching the U.S., where it has been delayed by regulators. Cipla Ltd. and Ranbaxy Laboratories Ltd. are among six drugmakers…


Read More »
Patent

NOVARTIS LOSES AT THE HIGH COURT: FOCUS NOW SHIFTS TO IPAB


Many of you may have already heard the breaking news today……..the Madras High Court ruled against Novartis, holding that section 3(d) is not unconstitutional. It also ruled that it is not competent to adjudicate upon whether or not section 3(d) is TRIPS compliant. Not a very surprising result for SPICYIP, which had already predicted this outcome in an earlier post, noting as follows: “Which way is the court/IPAB likely to go? Difficult to tell at this stage, but to the…


Read More »
Patent

Its All In the Genes!


There is enough and more reason to celebrate every morning-celebration in lieu of the totality of existence and the existence of the individual self. The Guru of Joy, Sri Sri of the Art of living fame established the U.S.P ‘I belong’…… The simple ritual practiced at the commencement of every Art of Living session where the participants greet each other with a resplendent ‘I belong’ , on deeper analysis comes with a profound metaphysical and scientific import. The ‘cosmic connect’…


Read More »